Financial Ratios

GLAND PHARMA LTD.

NSE : GLANDBSE : 543245ISIN CODE : INE068V01023Industry : Pharmaceuticals & DrugsHouse : Private
BSE1761.750 (0 %)
PREV CLOSE ( ) 1761.75
OPEN PRICE ( ) 1743.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3898
TODAY'S LOW / HIGH ( )1735.65 1778.00
52 WK LOW / HIGH ( )861.5 2195.75
NSE1763.60-0.8 (-0.05 %)
PREV CLOSE( ) 1764.40
OPEN PRICE ( ) 1740.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 96212
TODAY'S LOW / HIGH( ) 1736.00 1779.70
52 WK LOW / HIGH ( )861 2194
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)47.1173.7860.9549.88291.65
   CEPS(Rs)56.0180.4966.9855.9834.45
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)482.79434.87359.30234.251847.12
   Tax Rate(%)26.0025.1325.3122.1634.16
Margin Ratios
   Core EBITDA Margin(%)28.1634.3337.6136.2834.55
   EBIT Margin(%)29.1936.9138.6537.9833.75
   Pre Tax Margin(%)28.9936.7938.5537.7133.58
   PAT Margin (%)21.4527.5428.7929.3522.11
   Cash Profit Margin (%)25.5130.0531.6432.9426.12
Performance Ratios
   ROA(%)9.3416.9218.8420.3214.01
   ROE(%)10.2818.6220.9723.8117.14
   ROCE(%)13.9724.8628.0030.6826.11
   Asset Turnover(x)0.440.610.650.690.63
   Sales/Fixed Asset(x)1.652.512.492.051.80
   Working Capital/Sales(x)0.590.840.751.061.12
Efficiency Ratios
   Fixed Capital/Sales(x)0.610.400.400.490.56
   Receivable days97.7872.4067.0876.7887.61
   Inventory Days158.00102.05107.06115.61127.19
   Payable days113.9374.3396.62151.77215.21
Valuation Parameters
   PER(x)26.9344.3140.660.000.00
   PCE(x)22.6540.6236.990.000.00
   Price/Book(x)2.637.526.900.000.00
   Yield(%)0.000.000.00
   EV/Net Sales(x)4.7411.5110.84-0.50-0.36
   EV/Core EBITDA(x)13.6129.1926.12-1.19-0.92
   EV/EBIT(x)16.2331.1728.05-1.30-1.06
   EV/CE(x)2.157.075.78-0.36-0.26
   M Cap / Sales5.7812.2111.710.000.00
Growth Ratio
   Net Sales Growth(%)-17.8227.0831.5128.8126.19
   Core EBITDA Growth(%)-27.4220.7031.2838.2335.62
   EBIT Growth(%)-35.0021.3733.8244.9536.43
   PAT Growth(%)-36.0021.5829.0071.0240.73
   EPS Growth(%)-36.1521.0522.19-82.9040.73
Financial Stability Ratios
   Total Debt/Equity(x)0.000.000.000.000.00
   Current Ratio(x)9.4310.0410.007.934.43
   Quick Ratio(x)6.778.017.515.822.71
   Interest Cover(x)142.41309.98392.34139.24193.80
   Total Debt/Mcap(x)0.000.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.